Chamberlain PR wins Novartis diabetes drug brief following competitive pitch

Novartis has handed a comms account for diabetes drug Galvus to Chamberlain PR following a four-way pitch.

Account win: anti-diabetic drug Galvus
Account win: anti-diabetic drug Galvus

Chamberlain fought off Hill & Knowlton, Chandler Chicco and incumbent Fleishman-Hillard, which has handled the account for the past six years, to win the business.

The pitch was overseen by Rebecca Fisher-Pollard in the Novartis pharma comms team.

The business is expected to be transferred immediately.

Galvus is an oral anti-diabetic drug that helps to reduce hyperglycemia (high blood sugar) in Type 2 diabetics.

Type 2 diabetes is a condition that affects more than two million people in the UK and occurs when the pancreas does not manufacture enough insulin to meet a person’s needs, or the insulin is not metabolised effectively.

Chamberlain PR referred all calls to the client. Novartis said that a decision on the account would be made in ‘due course’.

Chamberlain has had a resurgence since the appointment of former Cohn & Wolfe senior director Mark Cater as managing director in March.

Cater was previously C&W regional director for the EMEA region, a role he took in 2008. Prior to that, he was head of GCI before it merged with C&W.

Since the beginning of the year, Chamberlain has picked up accounts including drugs firm Mundipharma, to handle  company-wide comms.

Chamberlain launched a London office in 2008, which was initially headed by MD Amanda Moulson.

However, she stepped down after just a year and moved to Ketchum in March 2009, taking the post of associate director in the senior healthcare team.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in